Krilogy Financial’s Iterum Therapeutics ITRM Stock Holding History

Krilogy Financial’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,761	Closed	-$1.74K	–	1111
2026 Q1	$1.74K	Buy	69,761 +29,761	+74%	+$7.46K	﹤0.01%	981
2025 Q4	$13.4K	Hold	40,000	–	–	﹤0.01%	920
2025 Q3	$24.6K	Buy	+40,000	New	+$31.3K	﹤0.01%	859
2023 Q2	–	Sell	-20,000	Closed	-$20K	–	293
2023 Q1	$20K	Hold	20,000	–	–	﹤0.01%	398
2022 Q4	$16.8K	Hold	20,000	–	–	﹤0.01%	378
2022 Q3	$32K	Buy	20,000 +6,667	+50%	+$20.2K	﹤0.01%	304
2022 Q2	$40K	Buy	+13,333	New	+$49.9K	﹤0.01%	307
2021 Q4	–	Sell	-5,400	Closed	-$45K	–	281
2021 Q3	$45K	Buy	5,400 +3,333	+161%	+$41.1K	﹤0.01%	266
2021 Q2	$72K	Buy	+2,067	New	+$44.8K	0.01%	270

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Krilogy Financial's ITRM Position: Q2 2026 in Review

Krilogy Financial sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 69,761 shares — an estimated $1.74K sold.

Krilogy Financial first reported a position in ITRM in Q2 2021 and held it in 9 quarters. The position peaked at $72K in Q2 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Krilogy Financial reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Krilogy Financial sold 69,761 Iterum Therapeutics shares in Q2 2026, an estimated $1.74K.
Krilogy Financial first reported a position in Iterum Therapeutics in Q2 2021 and held it in 9 quarters.
Krilogy Financial's Iterum Therapeutics position peaked at $72K in Q2 2021.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.